Within the first few weeks, she lost half a stone
Several studies have tested GLP-1 and combination medications for people with MASLD who have not yet progressed to MASH and have little or no fibrosis Another dual GLP-1/glucagon agonist, pemvidutide, reduced liver fat content by up to 69% in people with MASLD and no significant fibrosis, compared with 4% in the placebo group, and more than half achieved normal liver fat levels
Common solvents include bacteriostatic water, sterile saline, acidic buffers, and selected analytical-grade organic solvents
It helps the pancreas produce more insulin, which will lower blood sugar levels
Source: Rosenstock et al., The Lancet , June 6, 2026 (TRANSCEND-T2D-1)